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verse events, such as hyperlipidemia or hy-
perglycemia, should be discussed before
initiation of all protease inhibitor therapy.
Importantly, protease inhibitor–associated
unconjugated hyperbilirubinemia is not
associated with hepatotoxicity and is
completely reversible with discontinuation
of the protease inhibitor therapy [4, 5].
Therefore, additional consultation should
not be necessary in the setting of protease
inhibitor–associated hyperbilirubinemia.
Furthermore, in large trials, treatment dis-
continuation for hyperbilirubinemia oc-
curs rarely (!1%) [5, 6].
Rotger et al. do not explore the financial
cost of adding genetic screening before an-
tiretroviral therapy initiation, which would
be considerable if applied to the entire
HIV-infected population. The charge for
characterizing the UDP-glucuronosyltrans-
ferase 1A1 (UDPGT1A1) promoter can
be ∼$300. Cost-effectiveness analyses are
needed to determine the utility of such
screening measures. There are limited
data on the cost-effectiveness of genetic
screening for benign medical conditions
in HIV infection or other conditions. In
addition to its financial constraints, ge-
netic testing for the A(TA)7TAA allele
is almost completely unavailable in re-
source-limited settings. The authors also
do not discuss the burden of unneces-
sarily excluding from taking atazanavir or
indinavir substantial numbers of individ-
uals who are homozygous or heterozy-
gous for the A(TA)7TAA allele and will
not experience clinical jaundice.
Finally, the authors’ statement that the
A(TA)7TAA allele is associated with the
same “physiological effect” in nonwhite
populations should be made with caution.
Data from population studies indicate that
jaundice and hyperbilirubinemia are mul-
tifactorial in any given subject. For in-
stance, studies have indicated that Asian
infants have a higher—and African Amer-
ican infants a lower—incidence of hyper-
bilirubinemia, compared with their white
counterparts [7]. In work referred to
by Rotger et al., it was speculated that
the prevalence of the A(TA)7TAA variant
UDPGT1A1 promoter would therefore be
highest in Asian subjects, intermediate
in white subjects, and lowest in African
American subjects [8]. Contrary to this
expectation, the A(TA)7TAA variant was
most common among African Americans
and least common among subjects of
Asian origin [8]. Thus, although there is
a relationship between UDPGT1A1 pro-
moter repeat number and UDPGT1A1 ac-
tivity (and jaundice) within a racial group,
this correlation does not appear to hold
across ethnic groups.
In conclusion, although genetic screen-
ing offers much promise for decreasing the
frequency of adverse events related to med-
ications, we feel that such testing should be
reserved for the prevention of serious or
irreversible complications. Genetic screen-
ing for predisposition to a well-character-
ized, rapidly reversible adverse event that
is not associated with an undesirable med-
ical outcome seems unwarranted.
Richard E. Nettles, Michael J. Child,
Richard J. Bertz, and Steven Schnittman
Bristol-Myers Squibb Company,
Princeton, New Jersey
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Reply to Nettles et al.
To the Editor—Nettles et al.’s [1] com-
ments are consistent with the discussion
on the genetic predisposition to unconju-
gated hyperbilirubinemia in the article by
Rotger et al. [2]. However, the mechanism
leading to jaundice in newborns that Net-
tles et al. refer to is not the appropriate
example for discussing the genetics of Gil-
bert syndrome across ethnic groups. In ad-
dition, I disagree with 2 of their statements:
that stigmatizing a patient is a minor issue
as long as the treatment is discontinued and
that genetic screening should be reserved
for the prevention of serious, irreversible
complications.
In the management of a disease that ne-
cessitates long-term (lifelong) treatment,
“minor” adverse effects are frequent and
important [3]. A bout of diarrhea, some
nausea, and the occasional jaundice are not
to be minimized in importance, in partic-
ular when tolerance and toxicity currently
constitute the main reasons for treatment
discontinuation and change [4].
The cost of genetic testing is rapidly de-
creasing [5], and our understanding of
pharmacogenetics is increasing [6]. This
should allow for the development of tests
for genetic prediction of toxicity and ef-
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ficacy to guide treatment choice among
the multiple available antiretroviral drugs.
UGT1A1 is just one of the various genes
that could be included in a testing panel.
There is limited interest in interrogating
any single gene or in aiming analysis at
any particular drug.
Amalio Telenti
Institute of Microbiology, University of Lausanne,
and Swiss HIV Cohort Study, Lausanne, Switzerland
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Heterosubtypic Immunity
to Influenza: Right
Hypothesis, Wrong
Comparison
To the Editor—We read with interest Ep-
stein’s analysis of influenza in Cleveland
families [1]. We do not believe that the
results convincingly demonstrate hetero-
subtypic immunity—that is, immunity
that is elicited by influenza virus infection
and that partially prevents reinfection by
different influenza virus subtypes. Ep-
stein’s main conclusions are drawn from
the difference in influenza attack rates,
during the 1957 (pandemic) study year,
between children and adults who had had
influenza during earlier years (16/29 [55%]
vs. 1/18 [6%]; ). Yet a strong dif-Pp .002
ference was also observed between chil-
dren and adults who had not been infected
during earlier years (11/66 [17%] vs. 39/
75 [52%]; ), whereas no differenceP ! .001
was noted, in either adults (17% vs. 6%;
, Fisher’s exact test) or childrenPp .28
(55% vs. 52%; ), between individ-Pp .94
uals who had had influenza and those who
had not. Our interpretation of these find-
ings is that there was a difference, irre-
spective of prior exposure, between the
attack rate in children and that in adults.
This is not surprising [2]. Heterosubtypic
immunity to human influenza infection is
supported by both biological evidence
[3] and epidemiological theory [4, 5], al-
though, in our view, it cannot be deduced
from Epstein’s comparison of pandemic
attack rates in children versus those in
adults.
Fabrice Carrat and Audrey Lavenu
Epidemiology of Infectious Diseases Unit,
INSERM U707, and Groupe Hospitalier
Universitaire Est, Assistance Publique
Hoˆpitaux de Paris, and Universite´ Pierre
et Marie Curie (UPMC-Paris 6), Paris, France
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Reply to Carrat and Lavenu
To the Editor—Carrat and Lavenu com-
ment that the Cleveland Family Study data
do not convincingly demonstrate hetero-
subtypic immunity [1]. My analysis of the
subgroup of individuals who had had in-
fluenza during the earlier years of that
study showed an apparent protective effect
of prior illness in adults but not in chil-
dren; however, my article pointed out that
the difference in outcome in adults with
such episodes versus those without such
episodes was not statistically significant [2,
p. 51]. Carrat and Lavenu show this an-
other way, and I accept their point. They
and I reached essentially the same conclu-
sion—that “[t]hese historical data alone
cannot prove the existence of cross-pro-
tection” [2, p. 52]. I felt that the limited
data available, although not statistically
adequate, were important to describe, for
the following reasons:
1. Pandemic influenza caused illness
in a 3-fold-lower percentage of adults with
prior influenza during the study years than
those without (5.6% vs. 16.7%), suggest-
ing an impact of the prior infections, while
in children the percentage if anything was
slightly higher (55.2% vs. 52.0%). Also
note that the overall difference between
adults and children in the study popu-
lation was pronounced only in the pan-
demic year [2, table 1].
2. The study is valuable for the rich-
ness of clinical and laboratory details, and
it demonstrates that the low rates of illness
in adults were not due to lack of exposure;
most of these adults were exposed to the
pandemic virus within their own families.
3. These data describe experience
during a pandemic; the article does not
